| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyBiologicalProcess | nuclear-transcribed mRNA poly(A) tail shortening | 2.15e-07 | 33 | 33 | 4 | GO:0000289 | |
| GeneOntologyBiologicalProcess | nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 3.43e-06 | 65 | 33 | 4 | GO:0000288 | |
| GeneOntologyBiologicalProcess | nuclear-transcribed mRNA catabolic process | 5.68e-05 | 132 | 33 | 4 | GO:0000956 | |
| GeneOntologyBiologicalProcess | mRNA metabolic process | 7.62e-05 | 917 | 33 | 8 | GO:0016071 | |
| GeneOntologyBiologicalProcess | positive regulation of nuclear-transcribed mRNA poly(A) tail shortening | 2.23e-04 | 14 | 33 | 2 | GO:0060213 | |
| GeneOntologyBiologicalProcess | regulation of nuclear-transcribed mRNA poly(A) tail shortening | 2.94e-04 | 16 | 33 | 2 | GO:0060211 | |
| GeneOntologyBiologicalProcess | mRNA destabilization | 3.15e-04 | 206 | 33 | 4 | GO:0061157 | |
| GeneOntologyBiologicalProcess | RNA destabilization | 3.45e-04 | 211 | 33 | 4 | GO:0050779 | |
| GeneOntologyBiologicalProcess | positive regulation of mRNA catabolic process | 3.45e-04 | 211 | 33 | 4 | GO:0061014 | |
| GeneOntologyBiologicalProcess | negative regulation of translation | 4.78e-04 | 230 | 33 | 4 | GO:0017148 | |
| GeneOntologyBiologicalProcess | RNA catabolic process | 5.76e-04 | 432 | 33 | 5 | GO:0006401 | |
| GeneOntologyBiologicalProcess | positive regulation of mRNA metabolic process | 7.46e-04 | 259 | 33 | 4 | GO:1903313 | |
| GeneOntologyBiologicalProcess | nucleic acid catabolic process | 7.95e-04 | 464 | 33 | 5 | GO:0141188 | |
| GeneOntologyCellularComponent | P-body | 5.05e-04 | 102 | 32 | 3 | GO:0000932 | |
| GeneOntologyCellularComponent | cytoplasmic ribonucleoprotein granule | 7.26e-04 | 269 | 32 | 4 | GO:0036464 | |
| GeneOntologyCellularComponent | ribonucleoprotein granule | 9.24e-04 | 287 | 32 | 4 | GO:0035770 | |
| MousePheno | impaired contractility of urinary bladder detrusor smooth muscle | 1.55e-05 | 4 | 23 | 2 | MP:0000741 | |
| Domain | RRM | 2.27e-06 | 230 | 32 | 6 | PS50102 | |
| Domain | - | 3.19e-06 | 244 | 32 | 6 | 3.30.70.330 | |
| Domain | Nucleotide-bd_a/b_plait | 4.39e-06 | 258 | 32 | 6 | IPR012677 | |
| Domain | Ago_hook | 8.52e-06 | 3 | 32 | 2 | PF10427 | |
| Domain | TNRC6-PABC_bdg | 8.52e-06 | 3 | 32 | 2 | PF16608 | |
| Domain | TNRC6_PABC-bd | 8.52e-06 | 3 | 32 | 2 | IPR032226 | |
| Domain | Argonaute_hook_dom | 8.52e-06 | 3 | 32 | 2 | IPR019486 | |
| Domain | RRM | 3.15e-05 | 217 | 32 | 5 | SM00360 | |
| Domain | RRM_dom | 3.91e-05 | 227 | 32 | 5 | IPR000504 | |
| Domain | RRM_1 | 5.32e-03 | 208 | 32 | 3 | PF00076 | |
| Domain | UBA-like | 5.37e-03 | 64 | 32 | 2 | IPR009060 | |
| Domain | SAM_1 | 6.04e-03 | 68 | 32 | 2 | PF00536 | |
| Domain | SAM | 9.93e-03 | 88 | 32 | 2 | SM00454 | |
| Domain | SAM_DOMAIN | 1.15e-02 | 95 | 32 | 2 | PS50105 | |
| Domain | SAM | 1.20e-02 | 97 | 32 | 2 | IPR001660 | |
| Domain | - | 1.42e-02 | 106 | 32 | 2 | 1.10.150.50 | |
| Pathway | REACTOME_POST_TRANSCRIPTIONAL_SILENCING_BY_SMALL_RNAS | 3.80e-05 | 6 | 23 | 2 | MM15083 | |
| Pathway | REACTOME_POST_TRANSCRIPTIONAL_SILENCING_BY_SMALL_RNAS | 5.32e-05 | 7 | 23 | 2 | M46421 | |
| Pathway | REACTOME_REGULATION_OF_PTEN_MRNA_TRANSLATION | 9.10e-05 | 9 | 23 | 2 | M27810 | |
| Pathway | REACTOME_REGULATION_OF_NPAS4_MRNA_TRANSLATION | 9.10e-05 | 9 | 23 | 2 | M46436 | |
| Pathway | REACTOME_REGULATION_OF_CDH11_MRNA_TRANSLATION_BY_MICRORNAS | 1.14e-04 | 10 | 23 | 2 | M48013 | |
| Pathway | REACTOME_REGULATION_OF_NPAS4_GENE_EXPRESSION | 1.96e-04 | 13 | 23 | 2 | M46434 | |
| Pathway | REACTOME_REGULATION_OF_RUNX1_EXPRESSION_AND_ACTIVITY | 3.41e-04 | 17 | 23 | 2 | M27788 | |
| Pathway | REACTOME_REGULATION_OF_MITF_M_DEPENDENT_GENES_INVOLVED_IN_APOPTOSIS | 4.28e-04 | 19 | 23 | 2 | M48238 | |
| Pathway | REACTOME_TGFBR3_EXPRESSION | 9.38e-04 | 28 | 23 | 2 | M48253 | |
| Pathway | REACTOME_REGULATION_OF_HOMOTYPIC_CELL_CELL_ADHESION | 1.23e-03 | 32 | 23 | 2 | M48012 | |
| Pathway | REACTOME_REGULATION_OF_MECP2_EXPRESSION_AND_ACTIVITY | 1.23e-03 | 32 | 23 | 2 | M27900 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_BY_NPAS4 | 1.38e-03 | 34 | 23 | 2 | M46422 | |
| Pathway | REACTOME_GENE_SILENCING_BY_RNA | 1.44e-03 | 139 | 23 | 3 | M715 | |
| Pathway | REACTOME_ONCOGENE_INDUCED_SENESCENCE | 1.47e-03 | 35 | 23 | 2 | M27190 | |
| Pathway | REACTOME_NR1H3_NR1H2_REGULATE_GENE_EXPRESSION_LINKED_TO_CHOLESTEROL_TRANSPORT_AND_EFFLUX | 1.64e-03 | 37 | 23 | 2 | M29790 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_BY_VENTX | 2.01e-03 | 41 | 23 | 2 | M29748 | |
| Pathway | REACTOME_NR1H2_AND_NR1H3_MEDIATED_SIGNALING | 2.63e-03 | 47 | 23 | 2 | M29777 | |
| Pathway | REACTOME_GENE_SILENCING_BY_RNA | 2.86e-03 | 49 | 23 | 2 | MM14837 | |
| Pathway | REACTOME_SIGNALING_BY_TGFBR3 | 2.86e-03 | 49 | 23 | 2 | M48250 | |
| Pathway | REACTOME_ADHERENS_JUNCTIONS_INTERACTIONS | 3.98e-03 | 58 | 23 | 2 | M11980 | |
| Pathway | REACTOME_CA2_PATHWAY | 4.54e-03 | 62 | 23 | 2 | M27321 | |
| Pathway | REACTOME_G_ALPHA_Q_SIGNALLING_EVENTS | 4.63e-03 | 210 | 23 | 3 | MM15043 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_BY_MECP2 | 4.68e-03 | 63 | 23 | 2 | M27862 | |
| Pathway | REACTOME_G_ALPHA_Q_SIGNALLING_EVENTS | 5.08e-03 | 217 | 23 | 3 | M18437 | |
| Pathway | WP_MRNA_PROCESSING | 5.65e-03 | 451 | 23 | 4 | MM15946 | |
| Pubmed | 9.28e-07 | 2 | 34 | 2 | 29791863 | ||
| Pubmed | 2.78e-06 | 3 | 34 | 2 | 16880270 | ||
| Pubmed | Impact of scaffolding protein TNRC6 paralogs on gene expression and splicing. | 2.78e-06 | 3 | 34 | 2 | 34108231 | |
| Pubmed | 2.78e-06 | 3 | 34 | 2 | 31670606 | ||
| Pubmed | Bombesin-like peptide receptor gene expression, regulation, and function in fetal murine lung. | 5.56e-06 | 4 | 34 | 2 | 12959933 | |
| Pubmed | Two PABPC1-binding sites in GW182 proteins promote miRNA-mediated gene silencing. | 5.56e-06 | 4 | 34 | 2 | 21063388 | |
| Pubmed | The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts. | 1.10e-05 | 807 | 34 | 7 | 22681889 | |
| Pubmed | 1.16e-05 | 814 | 34 | 7 | 23251661 | ||
| Pubmed | 1.94e-05 | 7 | 34 | 2 | 19383768 | ||
| Pubmed | Functional dissection of the human TNRC6 (GW182-related) family of proteins. | 1.94e-05 | 7 | 34 | 2 | 19470757 | |
| Pubmed | 2.11e-05 | 347 | 34 | 5 | 16033648 | ||
| Pubmed | 5.07e-05 | 11 | 34 | 2 | 19549807 | ||
| Pubmed | 5.10e-05 | 209 | 34 | 4 | 36779422 | ||
| Pubmed | A Global Analysis of the Receptor Tyrosine Kinase-Protein Phosphatase Interactome. | 5.23e-05 | 420 | 34 | 5 | 28065597 | |
| Pubmed | 6.66e-05 | 80 | 34 | 3 | 35803934 | ||
| Pubmed | 6.79e-05 | 225 | 34 | 4 | 12168954 | ||
| Pubmed | 6.98e-05 | 733 | 34 | 6 | 34672954 | ||
| Pubmed | Mammalian miRNA RISC recruits CAF1 and PABP to affect PABP-dependent deadenylation. | 8.38e-05 | 14 | 34 | 2 | 19716330 | |
| Pubmed | RBM19 is essential for preimplantation development in the mouse. | 9.66e-05 | 15 | 34 | 2 | 19087264 | |
| Pubmed | GW182 proteins directly recruit cytoplasmic deadenylase complexes to miRNA targets. | 9.66e-05 | 15 | 34 | 2 | 21981923 | |
| Pubmed | The RNA-binding protein Snd1/Tudor-SN regulates hypoxia-responsive gene expression. | 1.18e-04 | 97 | 34 | 3 | 37151849 | |
| Pubmed | Autism-like phenotype and risk gene mRNA deadenylation by CPEB4 mis-splicing. | 1.41e-04 | 18 | 34 | 2 | 30111840 | |
| Pubmed | 1.45e-04 | 104 | 34 | 3 | 10470851 | ||
| Pubmed | 1.49e-04 | 105 | 34 | 3 | 9628581 | ||
| Pubmed | 1.54e-04 | 529 | 34 | 5 | 14621295 | ||
| Pubmed | A central chaperone-like role for 14-3-3 proteins in human cells. | 1.68e-04 | 861 | 34 | 6 | 36931259 | |
| Pubmed | EEF1D Promotes Glioma Proliferation, Migration, and Invasion through EMT and PI3K/Akt Pathway. | 1.93e-04 | 21 | 34 | 2 | 33029523 | |
| Pubmed | 2.12e-04 | 22 | 34 | 2 | 22187428 | ||
| Pubmed | 2.32e-04 | 23 | 34 | 2 | 28811219 | ||
| Pubmed | ATPase-Modulated Stress Granules Contain a Diverse Proteome and Substructure. | 2.47e-04 | 315 | 34 | 4 | 26777405 | |
| Pubmed | 3.08e-04 | 1371 | 34 | 7 | 36244648 | ||
| Pubmed | 3.95e-04 | 1429 | 34 | 7 | 35140242 | ||
| Pubmed | TRIM65 regulates microRNA activity by ubiquitination of TNRC6. | 4.27e-04 | 364 | 34 | 4 | 24778252 | |
| Pubmed | 6.04e-04 | 169 | 34 | 3 | 31462741 | ||
| Pubmed | A Degradation Motif in STAU1 Defines a Novel Family of Proteins Involved in Inflammation. | 6.51e-04 | 724 | 34 | 5 | 36232890 | |
| Pubmed | 6.71e-04 | 1116 | 34 | 6 | 31753913 | ||
| Pubmed | 7.17e-04 | 418 | 34 | 4 | 34709266 | ||
| Pubmed | An inducible CRISPR/Cas9 screen identifies DTX2 as a transcriptional regulator of human telomerase. | 7.25e-04 | 180 | 34 | 3 | 35198878 | |
| Pubmed | Large-scale characterization of HeLa cell nuclear phosphoproteins. | 8.78e-04 | 774 | 34 | 5 | 15302935 | |
| Pubmed | 8.93e-04 | 777 | 34 | 5 | 35844135 | ||
| Pubmed | Identification of proximal SUMO-dependent interactors using SUMO-ID. | 8.97e-04 | 444 | 34 | 4 | 34795231 | |
| Pubmed | 9.12e-04 | 446 | 34 | 4 | 24255178 | ||
| Interaction | CNOT6L interactions | 2.90e-07 | 93 | 31 | 5 | int:CNOT6L | |
| Interaction | CNOT7 interactions | 2.21e-06 | 140 | 31 | 5 | int:CNOT7 | |
| Interaction | CNOT4 interactions | 2.90e-06 | 65 | 31 | 4 | int:CNOT4 | |
| Interaction | PAN3 interactions | 2.90e-06 | 65 | 31 | 4 | int:PAN3 | |
| Interaction | GARRE1 interactions | 5.25e-06 | 167 | 31 | 5 | int:GARRE1 | |
| Interaction | CEP85 interactions | 5.57e-06 | 169 | 31 | 5 | int:CEP85 | |
| Interaction | CNOT2 interactions | 7.17e-06 | 178 | 31 | 5 | int:CNOT2 | |
| Interaction | ZFP36 interactions | 7.77e-06 | 181 | 31 | 5 | int:ZFP36 | |
| Interaction | SMG7 interactions | 7.91e-06 | 319 | 31 | 6 | int:SMG7 | |
| Interaction | SMG5 interactions | 8.11e-06 | 84 | 31 | 4 | int:SMG5 | |
| Interaction | ALG13 interactions | 8.20e-06 | 183 | 31 | 5 | int:ALG13 | |
| Interaction | GPBP1L1 interactions | 8.91e-06 | 86 | 31 | 4 | int:GPBP1L1 | |
| Interaction | CNOT3 interactions | 1.49e-05 | 207 | 31 | 5 | int:CNOT3 | |
| Interaction | DCAF4 interactions | 2.07e-05 | 378 | 31 | 6 | int:DCAF4 | |
| Interaction | MEX3B interactions | 2.09e-05 | 222 | 31 | 5 | int:MEX3B | |
| Interaction | ANKRD17 interactions | 2.27e-05 | 226 | 31 | 5 | int:ANKRD17 | |
| Interaction | CNOT9 interactions | 2.52e-05 | 231 | 31 | 5 | int:CNOT9 | |
| Interaction | CNOT11 interactions | 2.53e-05 | 112 | 31 | 4 | int:CNOT11 | |
| Interaction | UNK interactions | 3.18e-05 | 408 | 31 | 6 | int:UNK | |
| Interaction | R3HDM2 interactions | 4.41e-05 | 129 | 31 | 4 | int:R3HDM2 | |
| Interaction | CNOT10 interactions | 6.24e-05 | 141 | 31 | 4 | int:CNOT10 | |
| Interaction | TNRC6A interactions | 6.31e-05 | 280 | 31 | 5 | int:TNRC6A | |
| Interaction | TNRC6B interactions | 6.53e-05 | 282 | 31 | 5 | int:TNRC6B | |
| Interaction | DAZL interactions | 6.95e-05 | 145 | 31 | 4 | int:DAZL | |
| Interaction | CELF1 interactions | 7.21e-05 | 288 | 31 | 5 | int:CELF1 | |
| Interaction | FUBP3 interactions | 8.34e-05 | 297 | 31 | 5 | int:FUBP3 | |
| Interaction | AGO3 interactions | 8.57e-05 | 153 | 31 | 4 | int:AGO3 | |
| Interaction | CNOT6 interactions | 8.64e-05 | 56 | 31 | 3 | int:CNOT6 | |
| Interaction | CPEB4 interactions | 9.24e-05 | 156 | 31 | 4 | int:CPEB4 | |
| Interaction | CNOT1 interactions | 9.45e-05 | 305 | 31 | 5 | int:CNOT1 | |
| Interaction | NME7 interactions | 1.02e-04 | 160 | 31 | 4 | int:NME7 | |
| Interaction | YTHDF2 interactions | 1.05e-04 | 312 | 31 | 5 | int:YTHDF2 | |
| Interaction | PATL1 interactions | 1.50e-04 | 177 | 31 | 4 | int:PATL1 | |
| Interaction | AGO1 interactions | 1.71e-04 | 183 | 31 | 4 | int:AGO1 | |
| Interaction | FAM193A interactions | 1.75e-04 | 71 | 31 | 3 | int:FAM193A | |
| Interaction | CNOT8 interactions | 1.98e-04 | 74 | 31 | 3 | int:CNOT8 | |
| Interaction | FAM120C interactions | 2.01e-04 | 191 | 31 | 4 | int:FAM120C | |
| Interaction | GPBP1 interactions | 2.06e-04 | 75 | 31 | 3 | int:GPBP1 | |
| Interaction | RBM47 interactions | 2.59e-04 | 204 | 31 | 4 | int:RBM47 | |
| Interaction | RBMS1 interactions | 2.74e-04 | 207 | 31 | 4 | int:RBMS1 | |
| Interaction | ZC3H7A interactions | 3.16e-04 | 215 | 31 | 4 | int:ZC3H7A | |
| Interaction | OTUD4 interactions | 4.50e-04 | 236 | 31 | 4 | int:OTUD4 | |
| Interaction | RC3H2 interactions | 4.66e-04 | 667 | 31 | 6 | int:RC3H2 | |
| Interaction | RC3H1 interactions | 5.05e-04 | 677 | 31 | 6 | int:RC3H1 | |
| Interaction | YTHDF3 interactions | 5.26e-04 | 246 | 31 | 4 | int:YTHDF3 | |
| Interaction | DCP1B interactions | 5.40e-04 | 104 | 31 | 3 | int:DCP1B | |
| Interaction | HELZ interactions | 6.20e-04 | 257 | 31 | 4 | int:HELZ | |
| Interaction | PRRC2B interactions | 6.95e-04 | 265 | 31 | 4 | int:PRRC2B | |
| Interaction | AGO4 interactions | 7.80e-04 | 118 | 31 | 3 | int:AGO4 | |
| Interaction | KIZ interactions | 7.85e-04 | 27 | 31 | 2 | int:KIZ | |
| Interaction | SAMD4B interactions | 8.60e-04 | 122 | 31 | 3 | int:SAMD4B | |
| Interaction | PUM1 interactions | 9.36e-04 | 287 | 31 | 4 | int:PUM1 | |
| Interaction | MARF1 interactions | 9.88e-04 | 128 | 31 | 3 | int:MARF1 | |
| Interaction | TCHP interactions | 1.06e-03 | 131 | 31 | 3 | int:TCHP | |
| Interaction | UBAP2L interactions | 1.08e-03 | 298 | 31 | 4 | int:UBAP2L | |
| Interaction | EIF4ENIF1 interactions | 1.10e-03 | 300 | 31 | 4 | int:EIF4ENIF1 | |
| Interaction | YTHDF1 interactions | 1.13e-03 | 302 | 31 | 4 | int:YTHDF1 | |
| Interaction | TNRC6C interactions | 1.23e-03 | 138 | 31 | 3 | int:TNRC6C | |
| Interaction | OBI1 interactions | 1.25e-03 | 139 | 31 | 3 | int:OBI1 | |
| Interaction | PUM2 interactions | 1.39e-03 | 144 | 31 | 3 | int:PUM2 | |
| Interaction | CPEB1 interactions | 1.44e-03 | 146 | 31 | 3 | int:CPEB1 | |
| Interaction | SAV1 interactions | 1.59e-03 | 151 | 31 | 3 | int:SAV1 | |
| GeneFamily | RNA binding motif containing | 1.95e-04 | 213 | 25 | 4 | 725 | |
| GeneFamily | Ataxins|Trinucleotide repeat containing | 5.40e-04 | 25 | 25 | 2 | 775 | |
| GeneFamily | Sterile alpha motif domain containing | 6.53e-03 | 88 | 25 | 2 | 760 | |
| Coexpression | IVANOVA_HEMATOPOIESIS_MATURE_CELL | 3.36e-05 | 298 | 33 | 5 | M11205 | |
| Coexpression | IVANOVA_HEMATOPOIESIS_MATURE_CELL | 4.51e-05 | 317 | 33 | 5 | MM1163 | |
| Coexpression | GSE10147_IL3_VS_IL3_AND_HIVP17_STIM_PDC_UP | 5.50e-05 | 166 | 33 | 4 | M344 | |
| Coexpression | GSE29164_UNTREATED_VS_CD8_TCELL_AND_IL12_TREATED_MELANOMA_DAY3_DN | 1.13e-04 | 200 | 33 | 4 | M8485 | |
| Coexpression | GSE17721_4_VS_24H_CPG_BMDC_UP | 1.13e-04 | 200 | 33 | 4 | M4130 | |
| Coexpression | LAKE_ADULT_KIDNEY_C14_DISTAL_CONVOLUTED_TUBULE | 1.32e-04 | 208 | 33 | 4 | M39233 | |
| Coexpression | MURARO_PANCREAS_BETA_CELL | 1.46e-04 | 946 | 33 | 7 | M39169 | |
| Coexpression | LAKE_ADULT_KIDNEY_C5_PROXIMAL_TUBULE_EPITHELIAL_CELLS_STRESS_INFLAM | 1.64e-04 | 417 | 33 | 5 | M39224 | |
| Coexpression | LAKE_ADULT_KIDNEY_C3_PROXIMAL_TUBULE_EPITHELIAL_CELLS_S1_S2 | 1.66e-04 | 221 | 33 | 4 | M39222 | |
| Coexpression | MARTINEZ_RB1_TARGETS_UP | 1.97e-04 | 690 | 33 | 6 | M12224 | |
| ToppCell | Tracheal-NucSeq|Tracheal / Cell types per location group and 10X technology with lineage, and cell group designations | 3.45e-07 | 199 | 33 | 5 | 94b94b17ca18b8dc27b91da1f2ccf89e03cc7035 | |
| ToppCell | renal_cortex_nuclei|World / Celltypes from Cells and Nuclei per compartment and clinical group | 1.19e-05 | 192 | 33 | 4 | e8cc4d08fcfceeab75a02558817e4ccd7dbafe3a | |
| ToppCell | human_hepatoblastoma|World / Sample and Cell Type and Tumor Cluster (all cells) | 1.22e-05 | 193 | 33 | 4 | e6a688bc834f845ff64dae1be64f073eec5091a1 | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.22e-05 | 193 | 33 | 4 | 82e8a4c40299ffcdfd5a0da711bb9de6fb8a2eaa | |
| ToppCell | Brain_organoid-organoid_Tanaka_cellReport-6m|organoid_Tanaka_cellReport / Sample Type, Dataset, Time_group, and Cell type. | 1.40e-05 | 200 | 33 | 4 | 5ba4ed490c64b3bb738e7729669f893fa73aa56f | |
| Drug | Amprolium hydrochloride [137-88-2]; Up 200; 12.6uM; MCF7; HT_HG-U133A | 3.44e-07 | 196 | 33 | 6 | 1479_UP | |
| Drug | Melatonin [73-31-4]; Down 200; 17.2uM; MCF7; HT_HG-U133A | 8.13e-06 | 193 | 33 | 5 | 3293_DN | |
| Drug | Homosalate [118-56-9]; Down 200; 15.2uM; PC3; HT_HG-U133A | 8.55e-06 | 195 | 33 | 5 | 4533_DN | |
| Drug | 1,4-bis(diphenylphosphino)butane | 1.22e-05 | 4 | 33 | 2 | CID000082124 | |
| Drug | Rc 3120 | 2.03e-05 | 5 | 33 | 2 | CID005492660 | |
| Drug | L-365,260 | 2.08e-05 | 37 | 33 | 3 | CID000104929 | |
| Drug | AC1NUK9U | 4.26e-05 | 7 | 33 | 2 | CID005481220 | |
| Drug | Rc 3100 | 5.67e-05 | 8 | 33 | 2 | CID005487260 | |
| Drug | kuwanon | 7.29e-05 | 9 | 33 | 2 | CID005281667 | |
| Drug | 2-aminoacetophenone | 1.33e-04 | 12 | 33 | 2 | CID000011952 | |
| Drug | Ici 216140 | 1.33e-04 | 12 | 33 | 2 | CID005487263 | |
| Drug | Methazolamide [554-57-4]; Up 200; 17uM; MCF7; HT_HG-U133A | 1.69e-04 | 193 | 33 | 4 | 3474_UP | |
| Drug | Pentoxifylline [6493-05-6]; Down 200; 14.4uM; MCF7; HT_HG-U133A | 1.72e-04 | 194 | 33 | 4 | 6021_DN | |
| Drug | 2-propylpentanoic acid; Down 200; 500uM; MCF7; HT_HG-U133A | 1.76e-04 | 195 | 33 | 4 | 1665_DN | |
| Drug | Propoxycaine hydrochloride [550-83-4]; Down 200; 12uM; MCF7; HT_HG-U133A | 1.76e-04 | 195 | 33 | 4 | 3583_DN | |
| Drug | Spectinomycin dihydrochloride [21736-83-4]; Down 200; 9.8uM; MCF7; HT_HG-U133A | 1.79e-04 | 196 | 33 | 4 | 3327_DN | |
| Drug | Phenylpropanolamine hydrochloride [154-41-6]; Up 200; 21.4uM; MCF7; HT_HG-U133A | 1.79e-04 | 196 | 33 | 4 | 5298_UP | |
| Drug | Naloxone hydrochloride [357-08-4]; Down 200; 11uM; MCF7; HT_HG-U133A | 1.83e-04 | 197 | 33 | 4 | 5606_DN | |
| Drug | alpha-estradiol; Up 200; 0.01uM; MCF7; HT_HG-U133A_EA | 1.83e-04 | 197 | 33 | 4 | 1048_UP | |
| Drug | Meprylcaine hydrochloride [956-03-6]; Down 200; 14.8uM; MCF7; HT_HG-U133A | 1.83e-04 | 197 | 33 | 4 | 3544_DN | |
| Drug | Phyllolitorin | 1.83e-04 | 14 | 33 | 2 | CID005748287 | |
| Drug | Nefopam hydrochloride [23327-57-3]; Down 200; 13.8uM; PC3; HT_HG-U133A | 1.86e-04 | 198 | 33 | 4 | 3730_DN | |
| Drug | Naringenine [480-41-1]; Up 200; 14.6uM; MCF7; HT_HG-U133A | 1.86e-04 | 198 | 33 | 4 | 4422_UP | |
| Drug | Benzamil hydrochloride [2898-76-2]; Down 200; 11.2uM; PC3; HT_HG-U133A | 1.86e-04 | 198 | 33 | 4 | 3738_DN | |
| Drug | (-)-MK 801 hydrogen maleate [77086-19-2]; Down 200; 11.8uM; HL60; HT_HG-U133A | 1.86e-04 | 198 | 33 | 4 | 3081_DN | |
| Drug | Ranitidine hydrochloride [66357-59-3]; Down 200; 11.4uM; MCF7; HT_HG-U133A | 1.86e-04 | 198 | 33 | 4 | 2251_DN | |
| Drug | Tropine [120-29-6]; Down 200; 28.4uM; MCF7; HT_HG-U133A | 1.86e-04 | 198 | 33 | 4 | 3569_DN | |
| Drug | Baclofen (R,S) [1134-47-0]; Down 200; 18.8uM; MCF7; HT_HG-U133A | 1.90e-04 | 199 | 33 | 4 | 1536_DN | |
| Disease | alcohol consumption measurement | 4.11e-05 | 1242 | 32 | 8 | EFO_0007878 | |
| Disease | smoking status measurement | 2.02e-04 | 1160 | 32 | 7 | EFO_0006527 | |
| Disease | FEV/FEC ratio | 2.87e-04 | 1228 | 32 | 7 | EFO_0004713 | |
| Disease | bitter alcoholic beverage consumption measurement | 4.04e-04 | 133 | 32 | 3 | EFO_0010092 | |
| Disease | smoking cessation | 4.07e-04 | 325 | 32 | 4 | EFO_0004319 | |
| Disease | gestational age | 4.49e-04 | 138 | 32 | 3 | EFO_0005112 | |
| Disease | uric acid measurement | 4.71e-04 | 610 | 32 | 5 | EFO_0004761 | |
| Disease | risk-taking behaviour | 1.29e-03 | 764 | 32 | 5 | EFO_0008579 | |
| Disease | metabolic syndrome | 1.32e-03 | 200 | 32 | 3 | EFO_0000195 | |
| Disease | corpus callosum posterior volume measurement | 1.46e-03 | 52 | 32 | 2 | EFO_0010298 | |
| Disease | prostate carcinoma, type 2 diabetes mellitus | 1.88e-03 | 59 | 32 | 2 | EFO_0001663, MONDO_0005148 | |
| Disease | ceramide measurement | 2.09e-03 | 235 | 32 | 3 | EFO_0010222 | |
| Disease | body weight | 2.10e-03 | 1261 | 32 | 6 | EFO_0004338 | |
| Disease | chronotype measurement | 2.43e-03 | 882 | 32 | 5 | EFO_0008328 | |
| Disease | thyroxine measurement | 3.67e-03 | 83 | 32 | 2 | EFO_0005130 | |
| Disease | age at menarche | 3.74e-03 | 594 | 32 | 4 | EFO_0004703 | |
| Disease | cognitive function measurement | 3.98e-03 | 1434 | 32 | 6 | EFO_0008354 | |
| Disease | S-6-hydroxywarfarin to S-warfarin ratio measurement | 4.12e-03 | 88 | 32 | 2 | EFO_0803332 | |
| Disease | urate measurement, bone density | 4.33e-03 | 619 | 32 | 4 | EFO_0003923, EFO_0004531 | |
| Disease | social interaction measurement | 4.68e-03 | 94 | 32 | 2 | EFO_0009592 | |
| Disease | alcohol use disorder measurement, alcohol consumption measurement | 4.97e-03 | 97 | 32 | 2 | EFO_0007878, EFO_0009458 | |
| Disease | reticulocyte measurement | 5.18e-03 | 1053 | 32 | 5 | EFO_0010700 | |
| Disease | chronic obstructive pulmonary disease | 6.27e-03 | 688 | 32 | 4 | EFO_0000341 | |
| Disease | neuritic plaque measurement | 6.31e-03 | 349 | 32 | 3 | EFO_0006798 | |
| Disease | grip strength measurement | 6.36e-03 | 350 | 32 | 3 | EFO_0006941 | |
| Disease | cortical thickness | 6.53e-03 | 1113 | 32 | 5 | EFO_0004840 | |
| Disease | atrial fibrillation | 7.46e-03 | 371 | 32 | 3 | EFO_0000275 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| NDGQKNSTRLWNSQS | 501 | Q9UKH3 | |
| SWNNNDAAASLENSA | 336 | P20309 | |
| KSVAWQNSNEENSSS | 316 | Q8WZ64 | |
| SSSSANSQQGQWETG | 136 | Q8WXF8 | |
| NKSLSGSQTSSAWSN | 571 | Q96QP1 | |
| EAQDKANSASSHNWN | 501 | Q9Y4C8 | |
| NNSSSSSNSGWDQLS | 46 | P29558 | |
| TNATTFSNSQRWKQD | 91 | O14966 | |
| SFDSAWGQESAQNTK | 401 | P55081 | |
| TGNWNHAQDTKSSGQ | 671 | Q9BXT6 | |
| SGSGNKKSSNWNNNQ | 16 | Q8IYA8 | |
| NQQPSWDSEDSSNFK | 106 | P07492 | |
| WNALKPNTNSRDSSN | 426 | Q8IWU2 | |
| NKNHCESWESGNTNN | 636 | Q5VV63 | |
| NNNTAANGSSAGSAW | 46 | Q17RY0 | |
| NNDTKTWACSNVSEN | 46 | P54852 | |
| NSSNDNIQSITSGDW | 471 | P42658 | |
| RNENSGNSWNKNFGS | 1051 | Q99590 | |
| SSQNRQNWLAASESS | 826 | Q7Z2Y5 | |
| NSNGSQSSNSWKIDS | 161 | Q8IUI4 | |
| NSDWSSDTNRQGQQS | 771 | P78332 | |
| NWKERQSETSTQSQS | 436 | Q9UGK8 | |
| NGSQSSNSWKIDSLS | 316 | Q8TEQ0 | |
| ASGRKSSWQGENQSQ | 401 | Q9NQW5 | |
| WDNSSNAGFSEASNT | 511 | Q07837 | |
| VVSNDNTNKGWSGDN | 26 | P32247 | |
| DQQNGSATNAWDQSS | 346 | Q96HI0 | |
| SDNKACTGDSWTQNT | 721 | O94964 | |
| GQRDQSSWQNSDASQ | 1041 | Q9C0C2 | |
| DSSEDQVENSKNSWS | 1471 | Q70CQ2 | |
| ATQGAWQSSESSQAN | 371 | Q9UL49 | |
| WQSSESSQANLGEQA | 376 | Q9UL49 | |
| SNGNWKSSVRSTNNW | 221 | Q9H2Y7 | |
| QNSDDKLNGWQNSRD | 181 | Q9UPU9 | |
| NINPNNSSGWDESSK | 901 | Q8NDV7 | |
| SNSTTENNNGLGNWR | 271 | Q9UPQ9 | |
| SVQKSTGSKNDSWDN | 461 | Q9UPQ9 | |
| TGSKNDSWDNNNRST | 466 | Q9UPQ9 |